ICS 35.240.80 PREDBEŽNÁ SLOVENSKÁ TECHNICKÁ NORMA Jún 2024

STN P

Zdravotnícka informatika Klinické údaje Hlavné zásady harmonizácie termínov a indikátorov terapeutických indikácií (ISO 5499: 2024)

STN P
CEN ISO/TS 5499

84 8016

Health informatics - Clinical particulars - Core principles for the harmonization of therapeutic indications terms and identifiers (ISO/TS 5499:2024)

Táto norma obsahuje anglickú verziu európskej normy.
This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 05/24

Táto predbežná slovenská technická norma je určená na overenie. Prípadné pripomienky pošlite do februára 2026 Úradu pre normalizáciu, metrológiu a skúšobníctvo Slovenskej republiky.

Obsahuje: CEN ISO/TS 5499:2024, ISO/TS 5499:2024

obsahuje farebné strany

138551

TECHNICAL SPECIFICATION

SPÉCIFICATION TECHNIQUE

TECHNISCHE SPEZIFIKATION

CEN ISO/TS 5499

February 2024

ICS 35.240.80

English Version

Health informatics - Clinical particulars - Core principles for the harmonization of therapeutic indications terms and identifiers (ISO/TS 5499:2024)

Informatique de santé - Spécificités cliniques - Principes fondamentaux pour l'harmonisation des termes et identifiants des indications thérapeutiques (ISO/TS 5499:2024)

Medizinische Informatik - Klinische Besonderheiten - Grundprinzipien für die Harmonisierung von Indikationsbegriffen und -bezeichnungen (ISO/TS 5499:2024)

This Technical Specification (CEN/TS) was approved by CEN on 28 January 2024 for provisional application.

The period of validity of this CEN/TS is limited initially to three years. After two years the members of CEN will be requested to submit their comments, particularly on the question whether the CEN/TS can be converted into a European Standard.

CEN members are required to announce the existence of this CEN/TS in the same way as for an EN and to make the CEN/TS available promptly at national level in an appropriate form. It is permissible to keep conflicting national standards in force (in parallel to the CEN/TS) until the final decision about the possible conversion of the CEN/TS into an EN is reached.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.

EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Ref. No. CEN ISO/TS 5499:2024 E

Contents

Page

European foreword..... 3

European foreword

This document (CEN ISO/TS 5499:2024) has been prepared by Technical Committee ISO/TC 215 "Health informatics" in collaboration with Technical Committee CEN/TC 251 “Health informatics” the secretariat of which is held by NEN.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

Any feedback and questions on this document should be directed to the users’ national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to announce this Technical Specification: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

Endorsement notice

The text of ISO/TS 5499:2024 has been approved by CEN as CEN ISO/TS 5499:2024 without any modification.

Technical Specification

ISO/TS 5499

Health informatics — Clinical particulars — Core principles for the harmonization of therapeutic indications terms and identifiers

Informatique de santé — Spécificités cliniques — Principes fondamentaux pour l'harmonisation des termes et identifiants des indications thérapeutiques

First edition
2024-01

Reference number
ISO/TS 5499:2024(en)

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

Foreword ... **iv**
Introduction ... **v**
1 Scope ... **1**
2 Normative references ... **1**
3 Terms, definitions and abbreviated terms ... **1**
3.1 Terms and definitions ... 1
3.2 Abbreviated terms ... 3
4 Terminologies used for the coding of Therapeutic Indications ... **4**
4.1 General ... 4
4.2 SNOMED CT ... 4
4.3 MedDRA ... 4
4.4 ICD ... 4
4.5 MeSH ... 5
5 Use Cases for Coding of Therapeutic Indications ... **5**
5.1 General ... 5
5.2 IDMP data exchange between global regulators and bio/pharmaceutical companies during regulatory processes ... 6
5.2.1 Clinical Trials (Medicinal Product Development Lifecycle) ... 6
5.2.2 Regulatory Submission and Coded Labelling Information ... 6
5.2.3 Clinical protocol ... 8
5.2.4 Risk Management ... 8
5.3 Pharmacovigilance ... 9
5.3.1 General ... 9
5.3.2 Clinical information in the EHR supporting regulation for Pharmacovigilance ... 9
5.3.3 Identify potentially inappropriate prescribing/off-label use ... 10
5.4 Registries ... 10
6 Mapping principles specific to therapeutic indications ... **10**
6.1 Maps between Terminologies ... 10
6.1.1 General ... 10
6.1.2 Mapping Prerequisites ... 10
6.1.3 Required Processes ... 11
6.2 Therapeutic Indications - Mapping best practice principles and conventions ... 11
6.3 General mapping guidance ... 13
6.3.1 General ... 13
6.3.2 Mapping of national and regional terms ... 13
6.3.3 Regulatory agencies ... 13
Annex A (informative) **Implementations of the IDMP Therapeutic Indications Data Model** ... **16**
Bibliography ... **22**

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 215, *Health informatics,* in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 251, *Health informatics,* in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

Any feedback or questions on this document should be directed to the user’s national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

The need for improved communication between health agencies, hospitals, pharmacies, pharmaceutical companies and the general public about drug safety and efficacy information requires migration from manual text entry and unstructured data that cannot be coded, to a structured data model that is interoperable across the health care ecosystem[1]. The clinical particulars conceptual class of the ISO 11615 Identification of Medicinal Products (IDMP) data model captures information about a medicinal product's indication(s), contraindication(s), undesirable effect(s) and interactions. Within this conceptual class, the Therapeutic Indication subclass captures information about the therapeutic indication for the target disease or condition for which a medicinal product is authorized, under investigation, or utilized in clinical practice. Therapeutic indications can be described using free text as presented in approved product labelling documents, and as terms and codes from standard terminologies. Consistent and accurate coding of therapeutic indication terms is needed to support a variety of processes and is found in various terminological resources and official documents, which include epidemiological and real-world databases, electronic health records and health authority reporting processes. Therefore, a key principle for terminology mapping is that maps are based on specific use cases, and stakeholders who can provide feedback on the form, content and scope of the mapping should be engaged from the beginning of and throughout the mapping exercise.

A universally accepted terminology for coding therapeutic indications does not yet exist and is not feasible due to differing international medicinal product and healthcare regulations and reporting requirements. There is a difference between the therapeutic indication of a specific medicinal product and the diseases, conditions or problems listed in an electronic health record (EHR). While most EHRs will manage a problem list and/or a list of findings and diagnoses and a medication list, it is less frequent that the indication (or indications) for each specific medication is specified for a particular patient.

In medicinal product labels, a range of authorized indications is listed, often with qualifiers (diagnostic, preventive, curative, disease-modifying) or specified patient target groups. Sometimes, diseases or conditions are explicitly listed as not being indications for a specific drug. For example, "drug x" is not indicated in von Willebrand disease, or "drug y" is contraindicated with Haemophilia A. Use of medicinal products outside the authorized indications is considered off-label.

The indication wording, and thus the related coding, is based on a highly complex process over the years-long development of a pharmaceutical product. The relationship between a medicinal product and an indication is based on evidence from clinical trials, which are often comparative in nature (e.g. placebo versus active substance, or active substance A versus active substance B). Evidence synthesis in systematic reviews is often constrained by a Patient/intervention/comparator/outcome (PICO) statement, which results in a clinical recommendation to prefer or not to prefer the use of a particular medicinal product over another intervention for a particular patient (with a specific disease or condition), aiming at a specific outcome. In a regulatory document, this information is often reduced to a statement that "this medicinal product is indicated for ….".

In regulatory documents, the relationship is specified between a particular medicinal product (with specific substance(s), dose form(s), strength(s) and pack sizes), on the one hand and the indication(s), which are often specified in a detailed form. The formulation of this detailed indication often results from strong and intricate debate between the medical department of a pharmaceutical company, medical experts and regulators. The finesse of such formulation is often difficult to catch by any of the existing terminologies. For example, the therapeutic indications for a preparation that is licensed for over-the-counter (OTC) use can be more restrictive than the indications for the same preparation when prescribed by a clinician. For example, treatment of candidiasis in pregnancy using a clotrimazole must be under the direction of a physician; an OTC preparation is not authorized for this indication.

In handbooks of pharmacology and in drug classifications, indications might be formulated at a higher level of aggregation, and substances can be aggregated to drug classes. Hence, relationships between high level indications and drug classes (rather than individual substances) can be described.

Terminologies describing drug classes (e.g. the Anatomical Therapeutic Chemical (ATC) codes, SNOMED CT®[1)], Standard Drug Groups from WHO Drug, etc.) are built using different principles and dimensions (chemical class, anatomical target, therapeutic intent, mechanism of action, molecular target site), and exhibit variable levels of granularity. The same is true for terminologies describing diseases, conditions and signs and symptoms as proxies for indications. Therefore, using different terminologies (and maps between these terminologies) to establish relationships between medicinal products/drug classes and specific indications/high level indications can be bewilderingly complex. Hence, harmonization of terminologies for therapeutic indications should account for both the specific level of regulatory listing of authorized indications for specific medicinal products, as well as the relationship between high level aggregations of indications and substances.

The most common standard terminological resources used to describe and code medicinal product indication terms are the Medical Dictionary for Regulatory Activities (MedDRA®[2)]), SNOMED CT, the International Statistical Classification of Diseases and Related Health Problems (ICD™[3)]) and Medical Subject Headings (MeSH). Mappings between these terminological resources are necessary for documentation and reporting purposes; however, the different hierarchy levels and variation in the number of terms for each resource introduce significant complexity in the creation and maintenance of terminology maps. Map usage is often restricted by the limited availability of centrally provided and approved map sets and contributes to inefficiencies and redundant manual curation by individual stakeholders for specific use cases. Creation and maintenance of comprehensive maps between clinical terminologies to support coding of indication terms will thus liberate workforce effort and enable more efficient processes, responses and comprehensive reporting.

There are safety and maintenance implications when creating and applying maps that directly impact clinical care and decision-making. Therefore, a key principle is the requirement to identify the use case for any map before creating or using mappings. For example, there is an allowable semantic shift during mapping such as for statistics and billing because of aggregation to a group level, whereas in use cases to support clinical care at the individual (patient) level, no semantic shift can be tolerated because of potential safety issues. Thus, mappings between e.g. SNOMED CT and MedDRA are semantic maps of total meaning focused on adverse events. However, additional maps between these two terminologies with use cases focused on therapeutic indications are possibly needed, so a use case will need to be developed and tested against existing maps before deciding on next steps.

This document describes use cases and principles that are applicable for creation, assessment and selection of maps specific to Therapeutic Indications. This document thus refers to and builds on the following documents regarding terminologies and mapping:

— ISO/TR 14872 on core principles for maintenance of identifiers and terms

— ISO/TR 12300 on principles of mapping between terminological systems

— ISO/TS 21564 on terminology resource map quality measures (MapQual)

1) SNOMED CT® is the registered trademark of a product supplied by the International Health Terminology Standards Organization (IHTSDO). This information is given for the convenience of users of this document and does not constitute an endorsement by ISO of the product named.

2) MedDRA is the registered trademark of a product supplied by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) on behalf of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). This information is given for the convenience of users of this document and does not constitute an endorsement by ISO of the product named.

3) ICD™ (International Classification of Diseases) maintained by the World Health Organization is an example of a suitable product available commercially. This information is given for the convenience of users of this document and does not constitute an endorsement by ISO of this product.

Technical Specification **ISO/TS 5499:2024(en)**

Health informatics — Clinical particulars — Core principles for the harmonization of therapeutic indications terms and identifiers

1 Scope

The objective of this document is to establish common principles for the creation, assessment, selection and maintenance of maps between terminological resources used to describe and code IDMP therapeutic indications for investigational and medicinal products, medical devices, combination products, biologics and companion diagnostics. Core maintenance principles, such as reliability, reproducibility and quality assurance of the maps for future indication terminology use, are also discussed. The intended audience for this document includes:

a) Global regulators, pharmaceutical/biopharmaceutical companies, Clinical Research Organizations (CROs) and universities/scientific institutes involved in the development, authorization and marketing of medicinal products

b) Implementers of IDMP seeking more information about coding of Therapeutic Indications

c) Healthcare providers

d) Standards Organizations

e) Implementers and software vendors developing and implementing terminology map sets

f) Patients

2 Normative references

There are no normative references in this document.